BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

BRAF V600 mutations have been found in 1–2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50–80% of BRAF mutations in lung cancer are non-V600, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bracht, Jillian Wilhelmina Paulina, Karachaliou, Niki, Bivona, Trever, Lanman, Richard B., Faull, Iris, Nagy, Rebecca J., Drozdowskyj, Ana, Berenguer, Jordi, Fernandez-Bruno, Manuel, Molina-Vila, Miguel Angel, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770188/
https://www.ncbi.nlm.nih.gov/pubmed/31533235
http://dx.doi.org/10.3390/cancers11091381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770188/
https://www.ncbi.nlm.nih.gov/pubmed/31533235
http://dx.doi.org/10.3390/cancers11091381

Ejemplares similares